.gif?ad=20001&adview=true)
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Outpatient Practice Management Tips |
Department of Internal Medicine, Marshfield Clinic, Marshfield, Wisconsin
Department of Internal Medicine, Marshfield Clinic, and Clinical Research Center, Marshfield Clinic Research Foundation, Marshfield, Wisconsin
Department of Clinical Pathology, Microbiology Section, Marshfield Laboratories, and Clinical Research Center, Marshfield Clinic Research Foundation, Marshfield, Wisconsin
Department of Infectious Diseases, Marshfield Clinic, Marshfield, Wisconsin
Pulmonary and Critical Care, Marshfield Clinic, Marshfield, Wisconsin
REPRINT REQUESTS: Steven H. Yale, MD, Department of Internal Medicine, Marshfield Clinic, 1000 North Oak Avenue, Marshfield, WI 54449, Telephone: 715-387-5436, Fax: 715-389-3808, Email: yale.steven{at}mcrf.mfldclin.edu
Received: June 15, 2004.
Accepted: July 16, 2004.
Key Words: Tuberculosis • Tuberculin test • Mycobacterium tuberculosis • Interferon Type II/diagnostic use • BCG vaccine
Tuberculosis (TB) is a common cause of morbidity and mortality worldwide. The number of new cases continues to increase despite intense efforts to eradicate the disease. According to the World Health Organization, the global incidence rate of TB increased to 8.8 million cases in 2002 with a growth rate of 2.4% per year.1 In the United States, about half of the new cases occur in persons immigrating to this country.2
Treatment of persons with active TB is the number one priority targeted to prevent the spread of infection. A secondary priority, particularly in developed countries where there is a lower incidence of the disease, is the identification and treatment of persons with latent TB infection (LTBI).3 The majority of new cases of TB are derived from a pool of patients with LTBI. Thus, identifying and treating persons with latent infections is an important public health measure, since it not only prevents active TB from occurring in individuals with latent infection, but also prevents the interpersonal spread of the disease. Understanding the available tests and how to correctly interpret and apply the results is the first step in recognizing patients at risk and in providing appropriate treatment.
Studies available to diagnose LTBI
The goal of testing for LTBI is to identify persons who are at increased risk for developing TB and who would benefit from treatment of the infection.4 This includes healthcare workers and persons who have had recent contact with someone who has active TB as well as those with underlying medical conditions such as diabetes mellitus and lymphomas (tables 1
and 2). Since only persons who would benefit from treatment should be tested, a decision to test presupposes a decision to treat if the test result is positive. There are two tests available to confirm a diagnosis of LTBI: the tuberculin skin test, and the measurement of interferon-
in whole blood.
|
|
). The reaction is read 48 to 72 hours after injection. Reactivity to this antigen may persist up to 1 week facilitating accurate delayed interpretation.5
|
). To employ this technique, a line is lightly drawn with a pen in the horizontal and vertical planes until the edge of the induration is reached. To determine the size of the reaction, the induration is measured transversely to the long axis of the forearm from the most medial point.
|
The criteria for interpreting the reaction as positive, indicating the presence of TB infection, vary depending upon the characteristics of the person being tested. The general principle used in TB testing is that for patients with high-risk characteristics, the sensitivity of the tuberculin skin test is increased if a lower cut-off is used to define a positive test.
The whole blood interferon- test is a quantitative in vitro assay that evaluates the cell mediated immune response to M. tuberculosis. The test is based upon the principle that previously sensitized T lymphocytes release interferon- in response to stimulation by PPD. This assay has been shown to have excellent agreement with tuberculin skin testing.6 It should be noted that neither PPD nor the whole blood interferon- assay can distinguish between TB infection and bacilli Calmette-Guerin (BCG) induced reactivity. A novel assay that is not widely available measures the amount of interferon- released by T lymphocytes following exposure to the antigen ESAT-6 (normally absent in BCG) and may be useful for diagnosing LTBI in patients previously vaccinated with BCG.7
Testing for LTBI
The current recommendations from the American Thoracic Society and the Centers for Disease Control and Prevention are designed to focus tuberculin skin testing towards persons at high risk for developing active TB and who will receive treatment for LTBI if results are positive (table 1
).4 Unlike previous recommendations, age alone should not influence the decision to treat. In past recommendations age was used in the treatment decision because of the concerns related to the heightened awareness for increased risk of hepatotoxicity with isoniazid that increases with advancing age. In one early series, rates of hepatotoxicity were reported to be 3 out of every 1000 persons 20 to 34 years of age and 23 out of every 100 in persons 50 to 64 years of age.8 It should be kept in mind that mortality for isoniazid induced hepatotoxicity is very low, and complete recovery from nonfatal hepatotoxicity is the rule. Current recommendations state that persons who are at increased risk for developing active TB, because of certain medical conditions or because of exposure to infectious cases, and those for whom the risk of developing active TB exceeds the risk of developing isoniazid induced hepatotoxicity are candidates for LTBI testing. Persons should not undergo testing if they are not candidates for treatment. The risk of developing active TB is greatest immediately following exposure, therefore persons who have had a recent close contact with an individual with active TB represent a high priority group for LTBI testing.
Cut-off points for determining a positive tuberculin reaction
Regardless of a positive skin test result and prior to beginning treatment for patients with LTBI, a thorough assessment including chest radiographs and sputum analyses must be performed to exclude active TB infection. The threshold for determining a positive test is based upon different likelihoods of the tests representing true positives in the different settings. For example, persons at greatest risk have a lower threshold (5 mm diameter of induration) compared to those with few risk factors (15 mm diameter of induration). A person is identified as a "tuberculin converter," and thus recently infected, when the amount of induration found on tuberculin skin testing increases by 
10 mm within a 2-year period. Tuberculin conversion should be distinguished from the booster phenomenon in which a reaction to skin testing is initially negative and is found to be positive upon retesting 2 weeks later, even though the person is not newly infected. The booster phenomenon represents a false negative result in a person with prior LTBI due to waning immunity. To avoid misinterpretation of a person being a new tuberculin converter, two-step testing should be performed in all persons who are likely to be retested at a later date.
Many foreign countries continue to use BCG vaccination as part of their TB control program, particularly in infants. As mentioned previously, sensitivity to tuberculin is highly variable in persons vaccinated with BCG, and depends upon the strain of BCG used and the person receiving the vaccine. BCG vaccination is not routinely used in the United States because of the variable protective efficacy ranging from 0-80%.9 Although non-infected persons vaccinated with BCG may develop a false-positive result upon tuberculin skin testing, the majority (92%) of these persons are skin test negative, especially if they were vaccinated during infancy or early childhood.10 Thus, it is recommended that a previous history of BCG vaccination should be ignored when interpreting skin test results.
REFERENCES
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
